A Randomized Phase II Study of Nuclear Factor-kappa B (NF-κB) Inhibition During Induction Chemotherapy for Patients With Acute Myelogenous Leukemia
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 27
- 试验地点
- 1
- 主要终点
- Inhibition of NF-kB Target Transcripts and/or Inhibition of Drug Efflux in at Least 50% of Patients
研究概览
简要总结
This randomized phase II trial studies how well choline magnesium trisalicylate with idarubicin and cytarabine works in treating patients with acute myeloid leukemia. Drugs used in chemotherapy, such as choline magnesium trisalicylate, idarubicin, and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. It is not yet know whether choline magnesium trisalicylate and combination chemotherapy is more effective than combination chemotherapy alone in treating patients with acute myeloid leukemia.
详细描述
PRIMARY OBJECTIVES:
I. To determine temporal changes in leukemic cell nuclear factor of kappa light chain enhancer of B-cells 1 (NF-kB) activity when salicylate (choline magnesium trisalicylate) is administered to patients with acute myeloid leukemia (AML) during induction chemotherapy.
II. To determine toxicities associated with administration of salicylate in the setting of induction chemotherapy.
III. To determine if salicylate alters the expression of NF-kB-regulated genes in AML cells.
IV. To determine if NF-kB modulation by salicylate alters AML chemotherapy drug efflux.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have a diagnosis of non-M3 AML (patients with M3 subtype are excluded); determination of the presence of cytogenetic abnormalities will be by standard cytogenetics +/- fluorescent-in-situ (FISH) studies; additional molecular analyses for nucleophosmin (NPM) mutation and fms-related tyrosine kinase 3 (flt3) internal tandem duplication will be obtained as a part of standard care by institutional procedures
- •Leukemic blast count > 1500/mm^3 of peripheral blood
- •Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status =< 3
- •Total bilirubin < 2 times the institutional upper limit of normal (ULN)
- •Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) < 3 times the institutional ULN
- •Serum creatinine < 1.5 times the institutional ULN
- •Multi gated acquisition scan (MUGA) or echocardiogram with left ventricular ejection fraction (LVEF) > 50%
- •Women of childbearing potential must have a negative pregnancy test
- •No uncontrolled psychiatric illness that the principal investigator feels will compromise obtaining informed consent from a patient
- •Patient must be informed of the investigational nature of this study and must give written informed consent in accordance with institutional and federal guidelines; patients who do not provide informed consent will not be eligible for the study
排除标准
- •Any coexisting medical condition or medications precluding full compliance with any of the arms of the study
- •Allergies to any investigational drugs and/or to the chemotherapeutic agents
- •Allergies to any non-steroidal anti-inflammatory drugs (NSAIDs)/salicylates (e.g., aspirin)
- •Endoscopically documented upper or lower gastrointestinal (GI) related hemorrhage within last 6 months; also, patients with a clinical diagnosis of GI bleeding requiring blood transfusions will be excluded
研究组 & 干预措施
Arm II (chemotherapy)
Patients receive idarubicin IV on days 1- 3 and cytarabine IV continuously on days 1-7.
干预措施: idarubicin (Drug)
Arm I (choline magnesium trisalicylate and chemotherapy)
Patients receive choline magnesium trisalicylate PO every 8 hours on days 0-7, idarubicin IV on days 1-3, and cytarabine IV continuously on days 1-7.
干预措施: choline magnesium trisalicylate (Drug)
Arm I (choline magnesium trisalicylate and chemotherapy)
Patients receive choline magnesium trisalicylate PO every 8 hours on days 0-7, idarubicin IV on days 1-3, and cytarabine IV continuously on days 1-7.
干预措施: idarubicin (Drug)
Arm I (choline magnesium trisalicylate and chemotherapy)
Patients receive choline magnesium trisalicylate PO every 8 hours on days 0-7, idarubicin IV on days 1-3, and cytarabine IV continuously on days 1-7.
干预措施: cytarabine (Drug)
Arm I (choline magnesium trisalicylate and chemotherapy)
Patients receive choline magnesium trisalicylate PO every 8 hours on days 0-7, idarubicin IV on days 1-3, and cytarabine IV continuously on days 1-7.
干预措施: laboratory biomarker analysis (Other)
Arm II (chemotherapy)
Patients receive idarubicin IV on days 1- 3 and cytarabine IV continuously on days 1-7.
干预措施: cytarabine (Drug)
Arm II (chemotherapy)
Patients receive idarubicin IV on days 1- 3 and cytarabine IV continuously on days 1-7.
干预措施: laboratory biomarker analysis (Other)
结局指标
主要结局
Inhibition of NF-kB Target Transcripts and/or Inhibition of Drug Efflux in at Least 50% of Patients
时间窗: 24 hours
The clinical trial will be based on a sequential monitoring so that we will have a 90% confidence that choline magnesium trisalicylate (CMT) based modulation of NF-kB transcriptional targets and/or drug efflux occurs in at least 50% of patients.
次要结局
未报告次要终点
研究者
Roger Strair, MD, PhD
Professor of Medicine, RWJMS
Rutgers Cancer Institute of New Jersey